Literature DB >> 17149860

Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition.

Johannes Trapp1, Anne Jochum, Rene Meier, Laura Saunders, Brett Marshall, Conrad Kunick, Eric Verdin, Peter Goekjian, Wolfgang Sippl, Manfred Jung.   

Abstract

NAD+-dependent histone deacetylases, sirtuins, cleave acetyl groups from lysines of histones and other proteins to regulate their activity. Identification of potent selective inhibitors would help to elucidate sirtuin biology and could lead to useful therapeutic agents. NAD+ has an adenosine moiety that is also present in the kinase cofactor ATP. Kinase inhibitors based upon adenosine mimesis may thus also target NAD+-dependent enzymes. We present a systematic approach using adenosine mimics from one cofactor class (kinase inhibitors) as a viable method to generate new lead structures in another cofactor class (sirtuin inhibitors). Our findings have broad implications for medicinal chemistry and specifically for sirtuin inhibitor design. Our results also raise a question as to whether selectivity profiling for kinase inhibitors should be limited to ATP-dependent targets.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17149860     DOI: 10.1021/jm060118b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  29 in total

1.  SIRT1 contains N- and C-terminal regions that potentiate deacetylase activity.

Authors:  Min Pan; Hua Yuan; Michael Brent; Emily Chen Ding; Ronen Marmorstein
Journal:  J Biol Chem       Date:  2011-12-07       Impact factor: 5.157

2.  Parallel synthesis of a series of non-functional ATP/NAD analogs with activity against trypanosomatid parasites.

Authors:  Andreas Link; Philipp Heidler; Marcel Kaiser; Reto Brun
Journal:  Mol Divers       Date:  2009-05-30       Impact factor: 2.943

3.  Stalling of spliceosome assembly at distinct stages by small-molecule inhibitors of protein acetylation and deacetylation.

Authors:  Andreas N Kuhn; Maria A van Santen; Andreas Schwienhorst; Henning Urlaub; Reinhard Lührmann
Journal:  RNA       Date:  2008-11-24       Impact factor: 4.942

4.  3-(N-arylsulfamoyl)benzamides, inhibitors of human sirtuin type 2 (SIRT2).

Authors:  Soo Hyuk Choi; Luisa Quinti; Aleksey G Kazantsev; Richard B Silverman
Journal:  Bioorg Med Chem Lett       Date:  2012-03-03       Impact factor: 2.823

5.  Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5.

Authors:  Benjamin Maurer; Tobias Rumpf; Michael Scharfe; Diana A Stolfa; Martin L Schmitt; Wenjuan He; Eric Verdin; Wolfgang Sippl; Manfred Jung
Journal:  ACS Med Chem Lett       Date:  2012-10-06       Impact factor: 4.345

Review 6.  Using mitochondrial sirtuins as drug targets: disease implications and available compounds.

Authors:  Melanie Gertz; Clemens Steegborn
Journal:  Cell Mol Life Sci       Date:  2016-03-23       Impact factor: 9.261

7.  New chemical tools for probing activity and inhibition of the NAD+-dependent lysine deacylase sirtuin 2.

Authors:  Sören Swyter; Matthias Schiedel; Daria Monaldi; Sándor Szunyogh; Attila Lehotzky; Tobias Rumpf; Judit Ovádi; Wolfgang Sippl; Manfred Jung
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-06-05       Impact factor: 6.237

Review 8.  Sirtuin inhibitors as anticancer agents.

Authors:  Jing Hu; Hui Jing; Hening Lin
Journal:  Future Med Chem       Date:  2014-05       Impact factor: 3.808

Review 9.  Structural basis for sirtuin function: what we know and what we don't.

Authors:  Brandi D Sanders; Brittany Jackson; Ronen Marmorstein
Journal:  Biochim Biophys Acta       Date:  2009-09-18

10.  Identification and characterization of novel sirtuin inhibitor scaffolds.

Authors:  Brandi D Sanders; Brittany Jackson; Michael Brent; Alexander M Taylor; Weiwei Dang; Shelley L Berger; Stuart L Schreiber; Konrad Howitz; Ronen Marmorstein
Journal:  Bioorg Med Chem       Date:  2009-08-03       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.